Article Details

Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC

Retrieved on: 2024-01-30 19:57:09

Tags for this article:

Click the tags to see associated articles and topics

Priority Review Granted for Trastuzumab Deruxtecan; Would Be First Tumor-Agnostic ADC. View article details on HISWAI: https://www.ajmc.com/view/priority-review-granted-for-trastuzumab-deruxtecan-would-be-first-tumor-agnostic-adc

Excerpt

Trastuzumab deruxtecan currently has FDA approval as a second-line treatment for the treatment of certain patients with relapsed or refractory (R/R) ...

Article found on: www.ajmc.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up